Microneedling Alone vs Microneedling With PRP in the Treatment of Macular Amyloidosis; a Split Face Comparative Study

Comparison Between Efficacy and Safety of PRP With Microneedling and Microneedling Alone in Treatment of Macular Amyloidosis; a Split Face Blinded Non Randomized Control Trial With Dermoscopic and Histopathologic Evaluation

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07360860

Enrollment

Registered

2026-01-22

Start date

2026-01-10

Completion date

2026-06-30

Last updated

2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Amyloidosis

Keywords

Macular amyloidosis, Microneedling, PRP

Brief summary

This study is going to asses and compare the efficacy of treatment of macular amyloidosis using microneedling vs PRP with microneedling. Pruritus and pigmentation will be assessed.

Interventions

DEVICEmicroneedling

microneedling will be done for the one arm of macular amyloidosis

DEVICEmicroneedling with PRP

microneedling with PRP will be done on macular amyloidosis

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Investigator, Outcomes Assessor)

Intervention model description

Face split

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

• Both genders were included. * Patients above 18 years old. * Patients diagnosed by macular amyloidosis, proved by dermoscopy and histopathology.

Exclusion criteria

• Prior use of topical therapies in the previous 4 weeks. * Prior use of any procedures such as chemical peel or laser treatment in the previous 1 month. * Prior use of any systemic treatment for macular amyloidosis in the past 12 weeks. * Patients with other skin conditions (e.g., psoriasis, eczema). * Immunocompromised patients (HIV, chemotherapy). * Patients with history of any type of autoimmune disorders, coagulopathies, and keloid tendency. * Known or suspected allergy to ingredients

Design outcomes

Primary

Measure	Time frame	Description
Improvement of macular amyloidosis using microneedling or PRP with microneedling	3 months	1. The clinical assessment will be performed based on the photographs taken at baseline, after 1month, and 3 months of the last session. 2. Results will be measured by the Quartile grading scale: 1\< 25% improvement 2=25-\<50% improvement 3=50-\<75% improvement 4\> 75% improvement 3. Degree of improvement in dermoscopic features will be measured by scoring system as follows : 0-25% = 0 (no improvement) 26-50% = 1(mild improvement) 51-75% = 2 (moderate improvement) 76- 100% = 3 (marked improvement) 4. Patients' satisfaction: Visual Analog Score for pain 5.measuring the Treatment Satisfaction Questionnaire for Medication (TSQM) for effectiveness. 6\. TPhysician global satisfaction will be assessed. 0-3 (unsatisfied) 4-6 (satisfied) 7-10 (highly satisfied)

Contacts

CONTACTAmira Elbendary, MD

aelbendary@kasralainy.edu.eg+201552208664

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026